Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Segment Results
DHR logo

Danaher's Q3 Revenue Climbs 4.5% on Biotech Strength Amid Impairments

DHR10-QFiling Date: 10/21/2025
Danaher Corporation
Description

What this story covers

Danaher's Q3 revenues rose 4.5% to $6.0B, driven by 9% Biotech growth and steady Diagnostics, offset by Life Sciences softness and $548M impairments. Core sales up 3%, with strong liquidity ($4.3B operating cash) supporting repurchases and innovation in recurring consumables.

Story snapshot

CompanyDanaher Corporation
TickerDHR
VariantStandard detailed
Duration14:12
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000313616-25-000182

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in